Actelion regularly updates its investors on the growth opportunity of its innovative pipeline. Corporate events include the Annual General Meeting to update its shareholders, Media & Analyst Day when the full year results are presented, Research and Development Day when Actelion offers updates on its research capabilities and development pipeline, and periodic investor roadshows.

CORPORATE CALENDAR

Date Event Description
14 Feb 2017 FY Results 2016 Webcast with financial results for the full year of 2016
20 Apr 2017 Q1 Results 2017 Webcast with financial results for the first three months of 2017  
04 May 2017 AGM 2017 The Annual General Meeting 2017 of Shareholders to approve the Business Report 
20 Jul 2017  HY Results 2017 Webcast with financial results for the half year of 2017
 

Cardiovascular Pipeline udate

On 7 November 2016 Actelion held a conference call/webcast to discuss the udpate on Actelions cardiovascular pipeline.

2pm Basel / 1pm London / 8am New York

NINE MONTHS 2016 FINANCIAL REPORTING

On 20 October 2016 Actelion announced its financial results for the first nine months 2016.

Actelion’s New Dual orexin receptor antagonist (DORA)

On 7 July 2016 Actelion will held a conference call/webcast to discuss Actelion’s New Dual orexin receptor antagonist.

Actelion receives US FDA approval of Uptravi (selexipag)

On 5 January 2016 Actelion held a conference call/webcast to discuss US FDA approval of Uptravi (selexipag) for the treatment of pulmonary arterial hypertension.